A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.-MedSci.cn

A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.

Siena, S; Di Bartolomeo, M; Raghav, KPS; Masuishi, T; Loupakis, F; Kawakami, H; Yamaguchi, K; Nishina, T; Fakih, M; Elez, E; Rodriguez, J; Ciardiello, F; Saxena, K; Yamamoto, E; Bako, E; Okuda, Y; Shahidi, J; Grothey, A; Yoshino, T

JOURNAL OF CLINICAL ONCOLOGY, 2020; 38 (15):

科室
- - 订阅+
  - 更多科室
工具
服务